<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123626</url>
  </required_header>
  <id_info>
    <org_study_id>PQ-1123-001</org_study_id>
    <nct_id>NCT04123626</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene</brief_title>
  <acronym>AURORA</acronym>
  <official_title>A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProQR Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProQR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye
      (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or
      repeat doses. Single injections will be assessed in an open label way, and repeat injections
      will be assessed in a double-masked, randomized, sham-controlled fashion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      QR-1123 is an antisense oligonucleotide, designed to specifically target the mutant P23H
      messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein
      selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. It is
      hypothesized that the reduction of mutant P23H mRNA will reduce the deleterious effects of
      the dominant-negative protein and should result in increased function of WT rhodopsin protein
      in photoreceptors. Restoration of WT RHO function is expected to improve vision in patients
      with adRP due to the P23H mutation.

      The study will comprise up to 8 single dose and repeat dose cohorts. Prior to initiating a
      higher single dose cohort and/or prior to initiating repeat dose cohort(s), available safety
      and efficacy data will be reviewed by the DMC.

      In the single dose cohorts subjects will receive a single, unilateral IVT injection of
      QR-1123 in an open label fashion. In the repeat dose cohorts subjects will be randomized to
      receive either a unilateral IVT injection of QR-1123 every 3 months or a unilateral sham
      procedure every 3 months, in a double masked fashion. Subjects will be followed for safety,
      tolerability and efficacy for a total period of 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">October 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 7, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Single dose cohorts are open label. Repeat dose cohorts are randomized, double masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of ocular AEs</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Incidence and severity of ocular adverse events scored based on CTCAC in the study and fellow eye</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of non-ocular AEs</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Incidence and severity of non-ocular adverse events scored based on CTCAC in the study and fellow eye</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in BCVA</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Best corrected visual acuity (BCVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LLVA</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Low-luminance visual acuity (LLVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in DAC perimetry</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Dark adapted chromatic (DAC) perimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Static VF</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Static VF (Visual Field)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Microperimetry</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Microperimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in SD-OCT</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Spectral Domain-Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FST</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Full-field Stimulus Threshold (FST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Full-field ERG</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Full-field Electroretinogram (ERG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FAF</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Fundus Autofluorescence (FAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Contrast sensitivity</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Contrast sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Color vision</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Changes in Color vision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of systemic exposure after treatment with QR-1123</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serum levels of QR-1123</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Autosomal Dominant Retinitis Pigmentosa</condition>
  <condition>Eye Diseases</condition>
  <condition>Eye Diseases, Hereditary</condition>
  <condition>Retinal Dystrophies</condition>
  <condition>Retinal Disease</condition>
  <condition>Retinitis</condition>
  <condition>Vision Tunnel</condition>
  <condition>Vision Disorders</condition>
  <arm_group>
    <arm_group_label>QR-1123 Single dose - dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label Single dose cohort: dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QR-1123 Single dose - dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label Single dose cohort: dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QR-1123 Single dose - dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label Single dose cohort: dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QR-1123 Single dose - dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label Single dose cohort: dose level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat dose cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QR-1123</intervention_name>
    <description>unilateral IVT injection</description>
    <arm_group_label>QR-1123 Single dose - dose level 1</arm_group_label>
    <arm_group_label>QR-1123 Single dose - dose level 2</arm_group_label>
    <arm_group_label>QR-1123 Single dose - dose level 3</arm_group_label>
    <arm_group_label>QR-1123 Single dose - dose level 4</arm_group_label>
    <arm_group_label>Repeat dose cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment</description>
    <arm_group_label>Repeat dose cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Male or female, â‰¥ 18 years of age.

          2. Clinical presentation consistent with adRP, based on ophthalmic examinations.

          3. Impairment on VF in the opinion of the Investigator, as determined by perimetry.

          4. A molecular diagnosis of autosomal dominant form of RP with the P23H mutation in the
             RHO gene, based on genetic analysis.

          5. A clear ocular media and adequate pupillary dilation to permit good quality fundus
             imaging, as assessed by the Investigator.

        Main Exclusion Criteria:

          1. Presence of additional pathogenic mutations in genes (other than the P23H mutation in
             the RHO gene) associated with inherited retinal degenerative diseases or syndromes,
             based on genetic analysis (eg, Usher syndrome, Leber's congenital amaurosis, etc).

          2. Presence of any significant ocular or non-ocular disease/disorder (including
             medication and laboratory test abnormalities) which, in the opinion of the
             Investigator and with concurrence of the Medical Monitor, may either put the subject
             at risk because of participation in the study, may influence the results of the study,
             or the subject's ability to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ProQR Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>ProQR Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ProQR Clinical Trial Manager</last_name>
    <role>Study Director</role>
    <affiliation>ProQR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ProQR Clinical Trial Manager</last_name>
    <phone>+31(0)88 166 7000</phone>
    <email>info@proqr.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sue Anschutz-Rogers Eye Center, University of Colorado - Dept. of Ophthalmology</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Gerle</last_name>
      <phone>720-848-5096</phone>
      <email>RACHEL.GERLE@CUANSCHUTZ.EDU</email>
    </contact>
    <investigator>
      <last_name>M. Mathias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VitreoRetinal Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Zhang</last_name>
      <phone>352-300-8412</phone>
      <email>Jing@vra-pa.com</email>
    </contact>
    <investigator>
      <last_name>C Kay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners UK Ophthalmology - University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Reg</last_name>
      <phone>859-323-5868</phone>
      <email>Mreg4@uky.edu</email>
    </contact>
    <investigator>
      <last_name>R Maldonado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute, OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Voelker</last_name>
      <phone>503-494-0020</phone>
      <email>ordc@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>M Pennesi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tein Luu</last_name>
      <phone>214-363-3911</phone>
      <phone_ext>162</phone_ext>
      <email>tluu@retinafoundation.org</email>
    </contact>
    <investigator>
      <last_name>D Birch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adRP</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>P23H mutation</keyword>
  <keyword>Rhodopsin</keyword>
  <keyword>antisense oligonucleotide</keyword>
  <keyword>IVT</keyword>
  <keyword>autosomal dominant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
    <mesh_term>Eye Diseases, Hereditary</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

